MedPath

A prospective observational study for the diagnosis of non-alcoholic fatty liver disease with circulating natriuretic peptides

Not Applicable
Recruiting
Conditions
on-alcoholic fatty liver disease
Registration Number
JPRN-UMIN000048569
Lead Sponsor
Sapporo Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
500
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with a history diagnosed or treated with heart failure 2. Patients with alcohol intake (ethanol conversion) of 30g/day for males and 20g/day for females 3. Patients diagnosed with liver cirrhosis 4. Patients who have a history of infection or who are treated with hepatitis B or hepatitis C 5. Patients with intrahepatic malignant tumors such as hepatocellular carcinoma 6. Patients with a diagnosis of any malignancy 7. Patients under treatment with steroids, immunosuppressants, anticancer drugs, etc. 8. Patients diagnosed with chronic inflammatory diseases, such as autoimmune hepatitis, inflammatory bowel disease 9. Patients who do not consent to this study 10. Patients who are judged to be inappropriate as research subjects by the research director

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Correlation between the degree of hepatic steatosis/fibrosis by abdominal ultrasound and plasma ANP or BNP concentration
Secondary Outcome Measures
NameTimeMethod
1. Comparison of the diagnostic accuracy of liver fibrosis between the conventional scoring system to predict liver fibrosis (Fib-4 index, NAFLD fibrosis score) and plasma ANP or BNP concentration 2. Correlation between the presence or absence of arteriosclerosis diagnosed by ABI (ankle brachial pressure index) and plasma ANP/BNP concentrations 3. Correlation between liver fibrosis, arteriosclerosis, and RAS/fibrosis/inflammatory biomarkers
© Copyright 2025. All Rights Reserved by MedPath